[3H]PBC-264 [8017]
[3H]PBC-264
| SMILES | [3H]C([3H])([3H])C([3H])([3H])C(=O)N[C@@H](Cc1ccc(OS(=O)(=O)O)cc1)C(=O)N[C@@H](CCCC)NCC(=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCC)NC |
| InChIKey | VNNMDTHCFFZSSJ-LWSGDBLMSA-N |
| Sequence | YXGWXDF |
Chemical Properties
| Hydrogen bond acceptors | 14 |
| Hydrogen bond donors | 11 |
| Rotatable bonds | 33 |
| Log P | 1.414 |
| Molecular weight (Da) | 1071.5 |
| Stereochemistry info | partial |
| Radioactive | 3H |
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
[3H]PBC-264
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Surrogate |
| Approved drug | No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0